Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe

Both companies will expand their cooperation through the distribution of medical cannabis products in the highly attractive Czech and Swiss markets

Dusseldorf and Barcelona / Tel Aviv, October 6, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and Panaxia (TASE: PNAX), a global pharmaceutical company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality, today announced the signing of two addendums to their agreement to expand their collaboration into the Czech and Swiss markets.


Read more…